The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study

Bast, 1983, A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer, N. Engl. J. Med., 309, 883, 10.1056/NEJM198310133091503 Cannistra, 2003, Progress in the management of gynecologic cancer: consensus summary statement, J. Clin. Oncol., 21 Rustin, 1996, Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study, Ann. Oncol., 7, 361, 10.1093/oxfordjournals.annonc.a010602 Markman, 1991, Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin, J. Clin. Oncol., 9, 389, 10.1200/JCO.1991.9.3.389 Juretzka, 2007, CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy, Gynecol. Oncol., 104, 176, 10.1016/j.ygyno.2006.07.027 Markman, 2006, Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer, Gynecol. Oncol., 103, 195, 10.1016/j.ygyno.2006.02.024 Markman, 2006, Pretreatment CA-125 and risk of relapse in advanced ovarian cancer, J. Clin. Oncol., 24, 1454, 10.1200/JCO.2005.04.7373 Young, 1990, Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials, N. Engl. J. Med., 322, 1021, 10.1056/NEJM199004123221501 Torre, 2018, Ovarian cancer statistics, 2018, CA Cancer J. Clin., 68, 284, 10.3322/caac.21456 Bell, 2006, Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study, Gynecol. Oncol., 102, 432, 10.1016/j.ygyno.2006.06.013 Nagele, 1995, Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer, Obstet. Gynecol., 86, 259, 10.1016/0029-7844(95)00126-C Paramasivam, 2005, Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study, J. Clin. Oncol., 23, 5938, 10.1200/JCO.2005.08.151 Obermair, 2007, Preoperative serum CA125 in surgical stage 1 epithelial ovarian cancer, Gynecol. Oncol., 107, 357, 10.1016/j.ygyno.2007.07.001 Anderson, 1983, Analysis of survival by tumor response, J. Clin. Oncol., 1, 710, 10.1200/JCO.1983.1.11.710 Bottoni, 2015, The role of CA 125 as tumor marker: biochemical and clinical aspects, Adv. Exp. Med. Biol., 867, 229, 10.1007/978-94-017-7215-0_14 Johnson, 2008, The epidemiology of CA-125 in women without evidence of ovarian cancer in the prostate, lung, colorectal and ovarian Cancer (PLCO) screening trial, Gynecol. Oncol., 110, 383, 10.1016/j.ygyno.2008.05.006 Chan, 2008, Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers, Gynecol. Oncol., 109, 370, 10.1016/j.ygyno.2008.02.006 Lawrenson, 2009, Ovarian cancer: a clinical challenge that needs some basic answers, PLoS Med., 6, 10.1371/journal.pmed.1000025 Kang, 2010, Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer, Gynecol. Oncol., 116, 57, 10.1016/j.ygyno.2009.09.019 Prat, 2008, Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer, Ann. Oncol., 19, 327, 10.1093/annonc/mdm495 van Altena, 2010, CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study, Gynecol. Oncol., 119, 265, 10.1016/j.ygyno.2010.07.025 Xu, 2013, Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer, J. Ovarian. Res., 6, 31, 10.1186/1757-2215-6-31 Chan, 2010, The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study, Gynecol. Oncol., 116, 301, 10.1016/j.ygyno.2009.10.073 Corcoran, 2018, Application of cell-free DNA analysis to cancer treatment, N. Engl. J. Med., 379, 1754, 10.1056/NEJMra1706174 Pearl, 2015, Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs), Gynecol. Oncol., 137, 229, 10.1016/j.ygyno.2015.03.002 Parkinson, 2016, Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study, PLoS Med., 13, 10.1371/journal.pmed.1002198 Kurtz, 2019, Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction, Cell., 178, 699, 10.1016/j.cell.2019.06.011 Mannel, 2011, A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study, Gynecol. Oncol., 122, 89, 10.1016/j.ygyno.2011.03.013 Herzog, 2020, European society of medical oncology (ESMO) 2019 meeting report features practice changing data in gynecologic malignancies, Gynecol. Oncol., 156, 265, 10.1016/j.ygyno.2019.11.010 Chan, 2020, Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance, Gynecol. Oncol., 159, 604, 10.1016/j.ygyno.2020.09.017